FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013416851> ?p ?o ?g. }

• W2013416851 endingPage "501" @default.
• W2013416851 startingPage "449" @default.
• W2013416851 abstract "Introduction: Janus kinases (JAKs) comprise a family of four enzymes, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), centrally implicated in cell signaling processes important in cancer and immune-inflammatory diseases. Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor. There are many new JAK family enzyme inhibitors in the clinic now with a range of selectivity profiles. More selective JAK2 or JAK3 compounds are now coming through in considerable numbers and this review attempts to provide an update of the recent patent literature of those new compounds. An overview is given on the diversity of core structures employed for inhibitor design showing that the vast majority of compounds are based on classic ATP-competitive kinase inhibitor heterocycles. Areas covered: This review updates new patents claiming JAK2 and/or JAK3 inhibitors published from 2010 to 2012. Pre-2010 patents have been extensively covered in previous reviews. Comments on the context of each chemical series are given where applicable to orientate the readers on the bewildering array of molecular designs now available. This review does not cover JAK1 or TYK2 inhibitors but mention is made of these where they occur within series of JAK2/3 inhibitors. Given the overlap between many pharmacophores, it was not possible to completely separate inhibitors of JAK2 from JAK3, hence the material is organized by JAK2, JAK3 and JAK2/3 and within each section by alphabetical order of the patent assignee, some companies having published five or more patents, such as Ambit (10), Incyte (9), Galapagos (7), Almirall (6) and Biocryst (5). A total of 98 patents are reviewed herein. Expert opinion: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development. Selectivity against the four individual JAK family enzymes, JAK1, 2, 3 and TYK2, is now a key goal since they each play subtly different roles in cytokine-induced cell signaling. The future looks bright for patients as many new drugs are being developed and now combinations of JAK inhibitors with other targeted agents are being studied in the clinic. These advances are expected to lead to further significant progress improving patient outcomes and quality of life." @default.
• W2013416851 created "2016-06-24" @default.
• W2013416851 creator A5073127094 @default.
• W2013416851 creator A5076145300 @default.
• W2013416851 date "2013-02-01" @default.
• W2013416851 modified "2023-10-18" @default.
• W2013416851 title "Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012" @default.
• W2013416851 cites W1971291234 @default.
• W2013416851 cites W1973454407 @default.
• W2013416851 cites W1980568348 @default.
• W2013416851 cites W1981387370 @default.
• W2013416851 cites W1988726224 @default.
• W2013416851 cites W1991688187 @default.
• W2013416851 cites W1992197271 @default.
• W2013416851 cites W1995443841 @default.
• W2013416851 cites W2001251042 @default.
• W2013416851 cites W2001981959 @default.
• W2013416851 cites W2002782759 @default.
• W2013416851 cites W2010293026 @default.
• W2013416851 cites W2010641690 @default.
• W2013416851 cites W2010737710 @default.
• W2013416851 cites W2012828222 @default.
• W2013416851 cites W2014193241 @default.
• W2013416851 cites W2015684390 @default.
• W2013416851 cites W2016883830 @default.
• W2013416851 cites W2017715430 @default.
• W2013416851 cites W2019931350 @default.
• W2013416851 cites W2022819740 @default.
• W2013416851 cites W2025277793 @default.
• W2013416851 cites W2026115713 @default.
• W2013416851 cites W2029494734 @default.
• W2013416851 cites W2033294595 @default.
• W2013416851 cites W2038705787 @default.
• W2013416851 cites W2040551905 @default.
• W2013416851 cites W2043124942 @default.
• W2013416851 cites W2043184084 @default.
• W2013416851 cites W2044168067 @default.
• W2013416851 cites W2045469701 @default.
• W2013416851 cites W2049145190 @default.
• W2013416851 cites W2052731400 @default.
• W2013416851 cites W2055150750 @default.
• W2013416851 cites W2057360098 @default.
• W2013416851 cites W2061385654 @default.
• W2013416851 cites W2063657897 @default.
• W2013416851 cites W2075131681 @default.
• W2013416851 cites W2075490622 @default.
• W2013416851 cites W2076752985 @default.
• W2013416851 cites W2086117528 @default.
• W2013416851 cites W2090058745 @default.
• W2013416851 cites W2093804554 @default.
• W2013416851 cites W2093811818 @default.
• W2013416851 cites W2095543695 @default.
• W2013416851 cites W2105496815 @default.
• W2013416851 cites W2115351357 @default.
• W2013416851 cites W2115604425 @default.
• W2013416851 cites W2117026298 @default.
• W2013416851 cites W2121743767 @default.
• W2013416851 cites W2125810931 @default.
• W2013416851 cites W2127833800 @default.
• W2013416851 cites W2128124948 @default.
• W2013416851 cites W2129763580 @default.
• W2013416851 cites W2129927432 @default.
• W2013416851 cites W2132435276 @default.
• W2013416851 cites W2135699328 @default.
• W2013416851 cites W2139672588 @default.
• W2013416851 cites W2152673913 @default.
• W2013416851 cites W2162617912 @default.
• W2013416851 cites W2163087340 @default.
• W2013416851 cites W2163659364 @default.
• W2013416851 cites W2165495560 @default.
• W2013416851 cites W2166312789 @default.
• W2013416851 cites W2167265097 @default.
• W2013416851 cites W2167305078 @default.
• W2013416851 cites W2167617907 @default.
• W2013416851 cites W2169404371 @default.
• W2013416851 cites W2318002328 @default.
• W2013416851 cites W2333348199 @default.
• W2013416851 cites W4237200993 @default.
• W2013416851 doi "https://doi.org/10.1517/13543776.2013.765862" @default.
• W2013416851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23367873" @default.
• W2013416851 hasPublicationYear "2013" @default.
• W2013416851 type Work @default.
• W2013416851 sameAs 2013416851 @default.
• W2013416851 citedByCount "47" @default.
• W2013416851 countsByYear W20134168512013 @default.
• W2013416851 countsByYear W20134168512014 @default.
• W2013416851 countsByYear W20134168512015 @default.
• W2013416851 countsByYear W20134168512016 @default.
• W2013416851 countsByYear W20134168512017 @default.
• W2013416851 countsByYear W20134168512018 @default.
• W2013416851 countsByYear W20134168512019 @default.
• W2013416851 countsByYear W20134168512021 @default.
• W2013416851 countsByYear W20134168512022 @default.
• W2013416851 crossrefType "journal-article" @default.
• W2013416851 hasAuthorship W2013416851A5073127094 @default.
• W2013416851 hasAuthorship W2013416851A5076145300 @default.
• W2013416851 hasConcept C112392421 @default.
• W2013416851 hasConcept C130523297 @default.

• next